Research programme: Nociceptin/orphanin FQ peptide receptor agonist central therapeutics - Grunenthal
Alternative Names: NOP central - GrunenthalLatest Information Update: 28 Jul 2026
At a glance
- Originator Grunenthal
- Class Analgesics
- Mechanism of Action Nociceptin receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in Pain in Germany
- 22 Oct 2024 Pharmacodynamics data from a preclinical trial in Pain released by Grunenthal
- 27 Jun 2022 Nociceptin/orphanin FQ peptide receptor agonist central therapeutics - Grunenthal is available for licensing as of 27 Jun 2022. https://www.grunenthal.com/en/research-and-development/pain-research-and-development